Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.28
INVA's Cash-to-Debt is ranked lower than
91% of the 1046 Companies
in the Global Biotechnology industry.

( Industry Median: 55.72 vs. INVA: 0.28 )
Ranked among companies with meaningful Cash-to-Debt only.
INVA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.21  Med: 1.62 Max: 321.73
Current: 0.28
0.21
321.73
Equity-to-Asset -0.66
INVA's Equity-to-Asset is ranked lower than
97% of the 767 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. INVA: -0.66 )
Ranked among companies with meaningful Equity-to-Asset only.
INVA' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.39  Med: -0.42 Max: 0.67
Current: -0.66
-2.39
0.67
Debt-to-Equity -2.47
INVA's Debt-to-Equity is ranked lower than
99.99% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: 0.26 vs. INVA: -2.47 )
Ranked among companies with meaningful Debt-to-Equity only.
INVA' s Debt-to-Equity Range Over the Past 10 Years
Min: -7.71  Med: -0.54 Max: 1.11
Current: -2.47
-7.71
1.11
Debt-to-EBITDA 3.18
INVA's Debt-to-EBITDA is ranked lower than
67% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 1.94 vs. INVA: 3.18 )
Ranked among companies with meaningful Debt-to-EBITDA only.
INVA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -29.66  Med: -2.14 Max: 15.61
Current: 3.18
-29.66
15.61
Interest Coverage 4.21
INVA's Interest Coverage is ranked lower than
92% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. INVA: 4.21 )
Ranked among companies with meaningful Interest Coverage only.
INVA' s Interest Coverage Range Over the Past 10 Years
Min: 0.61  Med: 2.08 Max: 4.21
Current: 4.21
0.61
4.21
Piotroski F-Score: 8
Altman Z-Score: 4.59
Beneish M-Score: -1.95
WACC vs ROIC
15.29%
75.98%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 84.53
INVA's Operating Margin % is ranked higher than
99% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -105.96 vs. INVA: 84.53 )
Ranked among companies with meaningful Operating Margin % only.
INVA' s Operating Margin % Range Over the Past 10 Years
Min: -635.37  Med: -368.07 Max: 84.53
Current: 84.53
-635.37
84.53
Net Margin % 61.76
INVA's Net Margin % is ranked higher than
97% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -92.13 vs. INVA: 61.76 )
Ranked among companies with meaningful Net Margin % only.
INVA' s Net Margin % Range Over the Past 10 Years
Min: -3766.57  Med: -348.09 Max: 61.76
Current: 61.76
-3766.57
61.76
ROA % 35.28
INVA's ROA % is ranked higher than
98% of the 1052 Companies
in the Global Biotechnology industry.

( Industry Median: -32.93 vs. INVA: 35.28 )
Ranked among companies with meaningful ROA % only.
INVA' s ROA % Range Over the Past 10 Years
Min: -47.04  Med: -30.27 Max: 35.95
Current: 35.28
-47.04
35.95
ROC (Joel Greenblatt) % 252.37
INVA's ROC (Joel Greenblatt) % is ranked higher than
97% of the 1014 Companies
in the Global Biotechnology industry.

( Industry Median: -432.52 vs. INVA: 252.37 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
INVA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1062.05  Med: -383.21 Max: 468.83
Current: 252.37
-1062.05
468.83
3-Year Revenue Growth Rate 189.10
INVA's 3-Year Revenue Growth Rate is ranked higher than
98% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. INVA: 189.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
INVA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 1.3 Max: 191
Current: 189.1
0
191
GuruFocus has detected 2 Warning Signs with Innoviva Inc INVA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» INVA's 30-Y Financials

Financials (Next Earnings Date: 2018-04-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

INVA Guru Trades in Q1 2017

Jim Simons 42,920 sh (New)
Steven Cohen 712,400 sh (New)
Paul Tudor Jones 87,754 sh (+133.82%)
Joel Greenblatt 82,000 sh (-3.86%)
First Eagle Investment 3,126,898 sh (-8.87%)
Seth Klarman 11,573,663 sh (-22.49%)
» More
Q2 2017

INVA Guru Trades in Q2 2017

Michael Price 52,500 sh (New)
Joel Greenblatt 571,223 sh (+596.61%)
Steven Cohen 1,335,500 sh (+87.46%)
Jim Simons Sold Out
Seth Klarman Sold Out
First Eagle Investment 2,678,043 sh (-14.35%)
Paul Tudor Jones 37,369 sh (-57.42%)
» More
Q3 2017

INVA Guru Trades in Q3 2017

Jim Simons 1,060,380 sh (New)
Chuck Royce 756 sh (New)
Jeremy Grantham 14,600 sh (New)
Joel Greenblatt 589,067 sh (+3.12%)
Michael Price 52,500 sh (unchged)
Paul Tudor Jones Sold Out
First Eagle Investment 1,922,313 sh (-28.22%)
Steven Cohen 942,900 sh (-29.40%)
» More
Q4 2017

INVA Guru Trades in Q4 2017

Caxton Associates 18,037 sh (New)
Jim Simons 1,518,900 sh (+43.24%)
Steven Cohen 1,297,131 sh (+37.57%)
Chuck Royce 847 sh (+12.04%)
Jeremy Grantham 14,600 sh (unchged)
Michael Price 52,500 sh (unchged)
Joel Greenblatt 552,755 sh (-6.16%)
First Eagle Investment 1,288,150 sh (-32.99%)
» More
» Details

Insider Trades

Latest Guru Trades with INVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
First Eagle Investment 2017-12-31 Reduce -32.99%0.02%$11.73 - $14.75 $ 16.3523%1,288,150
Joel Greenblatt 2017-12-31 Reduce -6.16%0.01%$11.73 - $14.75 $ 16.3523%552,755
First Eagle Investment 2017-09-30 Reduce -28.22%0.02%$12.06 - $14.11 $ 16.3524%1,922,313
Joel Greenblatt 2017-09-30 Add 3.12%$12.06 - $14.11 $ 16.3524%589,067
First Eagle Investment 2017-06-30 Reduce -14.35%0.02%$11.44 - $14.42 $ 16.3530%2,678,043
Joel Greenblatt 2017-06-30 Add 596.61%0.09%$11.44 - $14.42 $ 16.3530%571,223
Michael Price 2017-06-30 New Buy0.09%$11.44 - $14.42 $ 16.3530%52,500
Seth Klarman 2017-06-30 Sold Out 1.9%$11.44 - $14.42 $ 16.3530%0
Seth Klarman 2017-04-30 Reduce -91.27%1.48%Premium Member Access $11.79 $ 16.3539%1,010,624
Seth Klarman 2017-03-31 Reduce -22.49%0.47%$10.43 - $13.83 $ 16.3539%11,573,663
First Eagle Investment 2017-03-31 Reduce -8.87%0.01%$10.43 - $13.83 $ 16.3539%3,126,898
Joel Greenblatt 2017-03-31 Reduce -3.86%$10.43 - $13.83 $ 16.3539%82,000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:XKRX:005250, NAS:EDIT, NAS:ICPT, NAS:CRSP, ROCO:4147, NAS:RGEN, NAS:PRTA, NAS:TBPH, TSE:4592, OSTO:VITR, NAS:SGMO, SZSE:002653, XMCE:ALM, NAS:MDGL, NAS:RXDX, NAS:ENTA, NAS:ARNA, NYSE:XON, NYSE:CBM, TSE:4565 » details
Traded in other countries:HVE.Germany,
Headquarter Location:USA
Innoviva Inc is a biopharmaceutical company that is engaged in the discovery, development and commercialization of small molecule medicines.

Theravance develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. The firm has gained approval for lead drug Vibativ for skin infections, but awaits a decision on usage for hospital-acquired pneumonia. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. The firm collaborates with and receives funding from GlaxoSmithKline on this venture.

Ratios

vs
industry
vs
history
PE Ratio 14.08
INVA's PE Ratio is ranked higher than
80% of the 266 Companies
in the Global Biotechnology industry.

( Industry Median: 28.26 vs. INVA: 14.08 )
Ranked among companies with meaningful PE Ratio only.
INVA' s PE Ratio Range Over the Past 10 Years
Min: 11.21  Med: 19.87 Max: 75.71
Current: 14.08
11.21
75.71
Forward PE Ratio 7.27
INVA's Forward PE Ratio is ranked higher than
97% of the 65 Companies
in the Global Biotechnology industry.

( Industry Median: 22.08 vs. INVA: 7.27 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 14.08
INVA's PE Ratio without NRI is ranked higher than
82% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 29.02 vs. INVA: 14.08 )
Ranked among companies with meaningful PE Ratio without NRI only.
INVA' s PE Ratio without NRI Range Over the Past 10 Years
Min: 11.21  Med: 19.87 Max: 75.71
Current: 14.08
11.21
75.71
Price-to-Owner-Earnings 15.18
INVA's Price-to-Owner-Earnings is ranked higher than
78% of the 144 Companies
in the Global Biotechnology industry.

( Industry Median: 35.22 vs. INVA: 15.18 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
INVA' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.06  Med: 22.66 Max: 321.75
Current: 15.18
12.06
321.75
PS Ratio 9.02
INVA's PS Ratio is ranked higher than
58% of the 731 Companies
in the Global Biotechnology industry.

( Industry Median: 11.11 vs. INVA: 9.02 )
Ranked among companies with meaningful PS Ratio only.
INVA' s PS Ratio Range Over the Past 10 Years
Min: 7.18  Med: 36.07 Max: 1600
Current: 9.02
7.18
1600
Price-to-Free-Cash-Flow 13.80
INVA's Price-to-Free-Cash-Flow is ranked higher than
76% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 30.41 vs. INVA: 13.80 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
INVA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.98  Med: 23.75 Max: 139.55
Current: 13.8
10.98
139.55
Price-to-Operating-Cash-Flow 13.80
INVA's Price-to-Operating-Cash-Flow is ranked higher than
75% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 26.94 vs. INVA: 13.80 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
INVA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 10.98  Med: 23.75 Max: 139.55
Current: 13.8
10.98
139.55
EV-to-EBIT 13.29
INVA's EV-to-EBIT is ranked higher than
73% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.83 vs. INVA: 13.29 )
Ranked among companies with meaningful EV-to-EBIT only.
INVA' s EV-to-EBIT Range Over the Past 10 Years
Min: -813.9  Med: -9.8 Max: 193.7
Current: 13.29
-813.9
193.7
EV-to-EBITDA 12.55
INVA's EV-to-EBITDA is ranked higher than
72% of the 285 Companies
in the Global Biotechnology industry.

( Industry Median: 20.69 vs. INVA: 12.55 )
Ranked among companies with meaningful EV-to-EBITDA only.
INVA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -387.5  Med: -9.4 Max: 360.3
Current: 12.55
-387.5
360.3
EV-to-Revenue 10.90
INVA's EV-to-Revenue is ranked higher than
55% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 12.21 vs. INVA: 10.90 )
Ranked among companies with meaningful EV-to-Revenue only.
INVA' s EV-to-Revenue Range Over the Past 10 Years
Min: 8.5  Med: 38.4 Max: 1849.5
Current: 10.9
8.5
1849.5
Current Ratio 20.49
INVA's Current Ratio is ranked higher than
95% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. INVA: 20.49 )
Ranked among companies with meaningful Current Ratio only.
INVA' s Current Ratio Range Over the Past 10 Years
Min: 2.41  Med: 5.55 Max: 20.49
Current: 20.49
2.41
20.49
Quick Ratio 20.49
INVA's Quick Ratio is ranked higher than
95% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.86 vs. INVA: 20.49 )
Ranked among companies with meaningful Quick Ratio only.
INVA' s Quick Ratio Range Over the Past 10 Years
Min: 2.41  Med: 5.49 Max: 20.49
Current: 20.49
2.41
20.49
Days Sales Outstanding 118.53
INVA's Days Sales Outstanding is ranked lower than
79% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: 65.03 vs. INVA: 118.53 )
Ranked among companies with meaningful Days Sales Outstanding only.
INVA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.92  Med: 42.61 Max: 456.63
Current: 118.53
2.92
456.63

Buy Back

vs
industry
vs
history
3-Year Dividend Growth Rate -100.00
INVA's 3-Year Dividend Growth Rate is ranked lower than
85% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 7.00 vs. INVA: -100.00 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
INVA' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: -100
Current: -100
5-Year Yield-on-Cost % 8.23
INVA's 5-Year Yield-on-Cost % is ranked higher than
91% of the 317 Companies
in the Global Biotechnology industry.

( Industry Median: 1.56 vs. INVA: 8.23 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
INVA' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.19  Med: 4.24 Max: 13.02
Current: 8.23
1.19
13.02
3-Year Average Share Buyback Ratio 2.40
INVA's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. INVA: 2.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
INVA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -140.4  Med: -10.2 Max: 2.4
Current: 2.4
-140.4
2.4

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.25
INVA's Price-to-Median-PS-Value is ranked higher than
91% of the 629 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. INVA: 0.25 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
INVA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.22  Med: 1.66 Max: 17.3
Current: 0.25
0.22
17.3
Earnings Yield (Greenblatt) % 7.51
INVA's Earnings Yield (Greenblatt) % is ranked higher than
93% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -7.37 vs. INVA: 7.51 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
INVA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -46.4  Med: -1.6 Max: 8.3
Current: 7.51
-46.4
8.3

More Statistics

Revenue (TTM) (Mil) $217.22
EPS (TTM) $ 1.16
Beta2.59
Short Percentage of Float70.81%
52-Week Range $11.02 - 17.21
Shares Outstanding (Mil)108.02

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 304 315 328
EBIT (Mil $)
EBITDA (Mil $) 283 294 306
EPS ($) 2.26 2.34 2.45
EPS without NRI ($) 2.26 2.34 2.45
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 88
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}